Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Frequently asked questions
What sector does Hemab Therapeutics Holdings, Inc. Common Stock (COAG) operate in?
Hemab Therapeutics Holdings, Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Hemab Therapeutics Holdings, Inc. Common Stock (COAG) current stock price?
As of the latest data, Hemab Therapeutics Holdings, Inc. Common Stock stock price is $49.16, with a previous close of $48.20. Hemab Therapeutics Holdings, Inc. Common Stock gained $0.96 in the last trading session, representing a 1.99% increase.
What is Hemab Therapeutics Holdings, Inc. Common Stock (COAG) current market capitalization?
Hemab Therapeutics Holdings, Inc. Common Stock market cap is approximately 2.30 billion.
What is Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Earnings Per Share (EPS)?
The trailing EPS is -$1.67, and the forward EPS is -$2.50.
What is Hemab Therapeutics Holdings, Inc. Common Stock (COAG) EBITDA?
Hemab Therapeutics Holdings, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -26.01 million.
Does Hemab Therapeutics Holdings, Inc. Common Stock (COAG) pay dividends?
No. Hemab Therapeutics Holdings, Inc. Common Stock does not pay a dividend.
What is Hemab Therapeutics Holdings, Inc. Common Stock (COAG) beta (volatility) score?
Hemab Therapeutics Holdings, Inc. Common Stock has a beta of -0.117, indicating lower volatility than the overall market.
